Researchers Create Promising Treatment

Gene Stowe and Marissa Gebhard | Nov. 30, 2012 | Notre Dame News

Norbert Wiech with students

University of Notre Dame alumnus Norbert Wiech (pictured right with students) founded Lysomics LLC to manage the clinical development needed to bring to market a promising new treatment for people with Niemann-Pick Type C (NPC) disease. FDA support is being sought for early clinical exploration of an approved drug to fight this rare disease that has no cure or treatment.

Lysomics is based on the work of Notre Dame professors of chemistry and biochemistry Olaf Wiest and Paul Helquist, and Frederick Maxfield at Cornell University’s Weill Medical College, to find treatments for NPC. NPC disease is a rare, fatal neurodegenerative disease that primarily strikes children before and during adolescence.

Read more at Notre Dame News


 by Daily Domer Staff

Posted In: Features